TNF and inflammatory bowel disease: Although multiple biologic treatments have been developed to revolutionize the management of IBD [e.g. anti-tumor necrosis factor α (anti-TNFα) and anti-interleukin] (3), there is still a significant unmet need of new targeted therapies for at least 40% inadequate-response patients (4).